About Careers Internship MedBlog Contact us

Japanese Drug Firm Agrees for Settlement With Hepatitis Infected Patients

by Medindia Content Team on November 4, 2007 at 12:07 PM
Japanese Drug Firm Agrees for Settlement With Hepatitis Infected Patients

A Japanese pharmaceutical company said Thursday it would start settlement talks with victims of hepatitis virus-tainted blood products as the government admitted its failure to prevent infections.

The government and the company estimate at least 10,000 Japanese people have been infected with potentially fatal hepatitis C after being administered with fibrinogen, which is used to stop bleeding.


Mitsubishi Tanabe Pharma Corp., a newly merged firm that incorporates the producer of the medical product under state licence, said it has agreed to reach a settlement in five lawsuits filed over the disease.

It said it has earmarked 2.1 billion yen (18.17 million dollars) to settle the case.

"We will respond to the calls for settlement discussions," Natsuki Hayama, company president, told a press conference.

The announcement came weeks after a court proposed settlement talks among the government, the company and the victims.

The government had denied its responsibility in the series of lawsuits.

But Prime Minister Yasuo Fukuda, who came to power a month ago, said Thursday he thought the government bore responsibility by approving the products.

Fibrinogen was widely used at Japanese hospitals until 1988, mostly during surgeries or after women give birth, even though the US government had warned the public of its danger in 1977.

The company has come under fire for its failure to respond to requests by victims for information disclosure and to swiftly notify people who might have contracted the disease.

Health Minister Yoichi Masuzoe said he has ordered the company to report to him every week on the progress in notifying victims of their infections.

"Stern measures must be taken if I feel they are not acting sincerely," he said.

Source: AFP
Font : A-A+



Recommended Readings

Latest Drug News

WHO Approves R21/Matrix-M, the World's Second Malaria Vaccine
R21/Matrix-M, the world's second malaria vaccine is readily deployable, and cost-effective making it prepared for distribution in areas where it is most essential.
New Inverse Vaccine Sparks Hope in Diabetes, Arthritis, and Crohn's Disease
The reverse vaccine uses the liver's natural "non-target" signals to prevent autoimmune responses against naturally decaying cells.
Projected Growth: Psychedelic Drug Market Anticipated to Hit $7.2 Billion by 2029
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
Promising ALS Drug Candidate Extends Lifespan
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-Calvulanate Vs Amoxicillin Preference in Child Sinusitis Treatment
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
Greetings! How can I assist you?MediBot

Japanese Drug Firm Agrees for Settlement With Hepatitis Infected Patients Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests